$CARM
Carisma Therapeutics Inc.

2018 Q2 Form 10-Q Financial Statement

#000148500318000058 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.350M $1.950M $2.210M
YoY Change 4.91% -11.76% 2.79%
% of Gross Profit
Research & Development $2.779M $3.255M $2.874M
YoY Change -4.47% 13.26% -37.95%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $80.00K
YoY Change -44.44% -37.5% 60.0%
% of Gross Profit
Operating Expenses $9.030M $4.007M $6.587M
YoY Change 22.86% -39.17% -2.83%
Operating Profit -$9.030M -$4.007M -$6.162M
YoY Change 22.86% -34.97% -5.92%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $72.00K $44.00K $101.0K
YoY Change 111.76% -56.44% -109.86%
Pretax Income -$8.960M -$3.960M -$6.060M
YoY Change 22.4% -34.65% -19.95%
Income Tax
% Of Pretax Income
Net Earnings -$8.958M -$3.963M -$6.061M
YoY Change 22.44% -34.61% -19.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$158.8K -$111.0K -$246.2K
COMMON SHARES
Basic Shares Outstanding 48.39M shares 43.11M shares 24.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.00M $19.70M $20.30M
YoY Change 298.73% -2.96% 51.49%
Cash & Equivalents $62.96M $19.69M $20.27M
Short-Term Investments
Other Short-Term Assets $800.0K $600.0K $700.0K
YoY Change 14.29% -14.29% 75.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.77M $20.33M $20.98M
YoY Change 287.45% -3.12% 51.96%
LONG-TERM ASSETS
Property, Plant & Equipment $421.0K $473.0K $714.0K
YoY Change -33.39% -33.75% 102.27%
Goodwill $13.06M $13.06M $16.86M
YoY Change -24.79% -22.53%
Intangibles $46.40M $46.40M $60.50M
YoY Change -23.31% -23.31%
Long-Term Investments
YoY Change
Other Assets $41.00K $19.00K $0.00
YoY Change -46.75%
Total Long-Term Assets $59.95M $59.97M $78.09M
YoY Change -23.72% -23.21% 14717.46%
TOTAL ASSETS
Total Short-Term Assets $63.77M $20.33M $20.98M
Total Long-Term Assets $59.95M $59.97M $78.09M
Total Assets $123.7M $80.29M $99.07M
YoY Change 30.16% -18.95% 591.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.310M $1.393M $1.214M
YoY Change 5.22% 14.74% -23.55%
Accrued Expenses $3.223M $3.853M $1.897M
YoY Change 29.33% 103.11% 286.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.533M $5.246M $3.226M
YoY Change 17.59% 62.62% 41.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $288.0K $260.0K $46.60M
YoY Change 94.59% -99.44% 57430.86%
Total Long-Term Liabilities $288.0K $260.0K $46.60M
YoY Change 94.59% -99.44% 57430.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.533M $5.246M $3.226M
Total Long-Term Liabilities $288.0K $260.0K $46.60M
Total Liabilities $4.821M $5.506M $66.20M
YoY Change 20.43% -91.68% 2701.52%
SHAREHOLDERS EQUITY
Retained Earnings -$165.3M -$156.3M -$129.4M
YoY Change 20.94% 20.79% -2.54%
Common Stock $77.00K $43.00K $25.00K
YoY Change 208.0% 72.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.06M $23.86M $32.91M
YoY Change
Total Liabilities & Shareholders Equity $123.7M $80.29M $99.07M
YoY Change 30.16% -18.95% 591.19%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$8.958M -$3.963M -$6.061M
YoY Change 22.44% -34.61% -19.98%
Depreciation, Depletion And Amortization $50.00K $50.00K $80.00K
YoY Change -44.44% -37.5% 60.0%
Cash From Operating Activities -$5.600M -$4.383M -$5.195M
YoY Change 24.17% -15.63% -39.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K $80.00K
YoY Change -100.0% -87.5%
Cash From Investing Activities $0.00 $5.000K $76.00K
YoY Change -100.0% -93.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.376M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.88M $9.386M $45.00K
YoY Change 20757.78% -100.32%
NET CHANGE
Cash From Operating Activities -5.600M -$4.383M -$5.195M
Cash From Investing Activities 0.000 $5.000K $76.00K
Cash From Financing Activities 48.88M $9.386M $45.00K
Net Change In Cash 43.28M $5.008M -$5.074M
YoY Change -1057.52% -198.7% -77.61%
FREE CASH FLOW
Cash From Operating Activities -$5.600M -$4.383M -$5.195M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
907000 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1393000 USD
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 ebio Working Capital Net
WorkingCapitalNet
15100000 USD
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48390072 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2018Q1 dei Trading Symbol
TradingSymbol
EBIO
CY2018Q1 ebio Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
CY2018Q1 ebio Class Of Warrant Or Right Price Per Share
ClassOfWarrantOrRightPricePerShare
0.125
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3813000 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3853000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000 USD
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
237000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170330000 USD
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
180109000 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2661741 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20250354 shares
CY2017Q4 us-gaap Assets
Assets
75097000 USD
CY2018Q1 us-gaap Assets
Assets
80292000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14981000 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
20326000 USD
CY2017Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1500000 USD
CY2018Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1200000 USD
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
39600000 USD
CY2018Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
38400000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14680000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19688000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25352000 USD
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20278000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14690000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19698000 USD
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5074000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5008000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7968128 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34702565 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43105466 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34702565 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43105466 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
35000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
43000 USD
CY2017Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
2581000 USD
CY2018Q1 us-gaap Construction Payable Current
ConstructionPayableCurrent
2650000 USD
CY2018Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2018Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
82000 USD
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
49000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
896000 USD
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1000000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2017Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
76000 USD
CY2018Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2213000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1952000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
13064000 USD
CY2018Q1 us-gaap Goodwill
Goodwill
13064000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-453000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
486000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
123000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
85000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2017Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1000 USD
CY2018Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
127000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
236000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2018Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75097000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80292000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4720000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5246000 USD
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
425000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44000 USD
CY2018Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9386000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5195000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4383000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-6061000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3963000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
101000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
6587000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
4007000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6162000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4007000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34000 USD
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
70000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000 USD
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
215000 USD
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
101000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000 USD
CY2018Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
53000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
301000 USD
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
638000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9376000 USD
CY2017Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
76000 USD
CY2018Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
5000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40000 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2017Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000 USD
CY2018Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
10000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
522000 USD
CY2018Q1 us-gaap Revenues
Revenues
0 USD
CY2018Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
9000000 USD
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
7968128 shares
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
473000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2874000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3255000 USD
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
10000 USD
CY2018Q1 us-gaap Restricted Cash
RestrictedCash
10000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2017Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
100000 USD
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
111000 USD
CY2018Q1 us-gaap Restructuring Reserve
RestructuringReserve
58000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152331000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156294000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156300000 USD
CY2018Q1 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0 USD
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.13
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
425000 USD
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2018Q1 us-gaap Severance Costs1
SeveranceCosts1
100000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
244000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
401000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1580060 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.79
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150292 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
102500 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2695796 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2648004 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.16
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.13
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2586804 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.16
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.20
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.93
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18034000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
23858000 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24610000 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35674000 shares

Files In Submission

Name View Source Status
0001485003-18-000058-index-headers.html Edgar Link pending
0001485003-18-000058-index.html Edgar Link pending
0001485003-18-000058.txt Edgar Link pending
0001485003-18-000058-xbrl.zip Edgar Link pending
ebio-033118x10q.htm Edgar Link pending
ebio-033118x311.htm Edgar Link pending
ebio-033118x312.htm Edgar Link pending
ebio-033118x321.htm Edgar Link pending
ebio-20180331.xml Edgar Link completed
ebio-20180331.xsd Edgar Link pending
ebio-20180331_cal.xml Edgar Link unprocessable
ebio-20180331_def.xml Edgar Link unprocessable
ebio-20180331_lab.xml Edgar Link unprocessable
ebio-20180331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending